Cohen Enterprises, Inc. acquires Mangoceuticals, Inc. (2022)

Deal facts

Buyer: Cohen Enterprises, Inc.
Target: Mangoceuticals, Inc.
Deal value: Not disclosed
Announced: 23 June 2022
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

16 Jun 2022CompletedClosed
Cohen Enterprises, Inc. completes acquisition of Mangoceuticals, Inc.
Item 1.01 Entry into a Material Definitive Agreement. Mangoceuticals Sale On June 16, 2022, American International Holdings Corp. (the “ Company ”, “ we ” or “ us ”), entered into and closed the transactions contemplated by a Stock Purchase Agreement (the “ SPA ”), with Cohen Enterprises, Inc. (“ Cohen Enterprises ”), which entity is owned and controlled by Jacob D. Cohen, the Chief Executive Offi
Source

OpinionExit Mode editorial

We see a straightforward strategic acquisition in the healthcare sector where Cohen Enterprises, Inc. has completed its purchase of Mangoceuticals, Inc. The deal was announced on 23 June 2022 and has since closed. Both parties are based in the United States, which simplifies the regulatory landscape compared to cross-border transactions involving the UK or EU. The entire consideration was paid in cash, a structure that removes the uncertainty often associated with earn-outs or share-based payments. For the SME founder reading this, the clarity of a cash deal is a significant advantage, as it provides immediate liquidity and a clean exit without ongoing performance contingencies.

The strategic nature of this transaction suggests that the buyer identified specific capabilities or market access within Mangoceuticals that complement its existing portfolio. In the healthcare industry, such acquisitions often aim to integrate new product lines or secure distribution channels rather than simply expanding financial scale. The absence of a disclosed value in public records is not uncommon for private company transactions, yet the completion status confirms that both sides agreed on terms that satisfied their respective due diligence requirements. This outcome highlights the importance of aligning strategic fit with commercial terms, ensuring that the buyer sees clear value in the target's operations beyond just the balance sheet.

Regulatory clearance in a domestic US healthcare deal typically involves standard antitrust review, but the lack of reported hurdles indicates the transaction likely fell below thresholds that would trigger a lengthy investigation by the Federal Trade Commission. For founders navigating similar paths, the speed of completion often correlates with the simplicity of the consideration structure and the absence of complex change-of-control covenants. We believe this deal serves as a practical example of how a pure cash offer can streamline negotiations and accelerate the path to closing, provided the strategic rationale is sound and the regulatory environment is permissive.

Your immediate action this week should be to audit your current customer contracts for any change-of-control clauses that could be triggered by a potential buyer's entry. Many founders overlook these provisions until a deal is imminent, only to find that third-party consent is required to complete the sale. Identify which agreements need early engagement and prepare a summary of your key commercial relationships to present to any prospective acquirer. This preparation will prevent last-minute delays and demonstrate operational maturity during the due diligence phase.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2022 deals More strategic acquisition deals More from Cohen Enterprises, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history